Market Overview

Covidien Announces R&D Center in China

Covidien (NYSE: COV), a leading global provider of healthcare products, today announced the creation of its flagship research and development (R&D) center for China, which will be based in Shanghai.

The center, which will be fully functional by July 2012, will house two of Covidien's emerging market R&D organizations:

Tailored Products – will identify and develop products that are customized to meet the needs of China and other countries in the emerging markets

Breakthrough Platforms – will utilize the unique skill sets and expertise of employees in Asia to create and develop new medical device technologies.

“The establishment of this R&D facility is a first for Covidien in China,” said Dr. Dong Wu, Vice President, China R&D, Covidien. “We will be undertaking a range of cutting-edge activities that will create innovative products to help physicians improve the health of the people of China and of other markets worldwide.”

Posted-In: News

 

Most Popular

Related Articles (COV)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free